prenatal testing
Craig-Hallum Initiates Coverage of Myriad Genetics With a Buy Rating
Craig-Hallum expects stable Prolaris revenues and sees opportunities for significant growth in the hereditary cancer and prenatal testing markets.
JP Morgan Healthcare Conference, Day 4: Standard BioTools, Sera Prognostics, OraSure, Geneoscopy
Highlights from the fourth day included preliminary data from Sera Prognostics for its PreTRM blood test.
BillionToOne Raises $130M in Series D Financing Round
The Menlo Park, California-based company will use the funds to expand and scale its prenatal and oncology testing businesses.
Natera Reports 52 Percent Spike in Q1 Revenues, Raises Full-Year Guidance
The company beat analysts' estimates on the top and bottom lines with growth driven by increased testing volumes and improvements in average test selling price.
Myriad Genetics Q4, Full-Year Revenues Jump 11 Percent on Strong Test Volume Growth
For the three months ended Dec. 31 Myriad reported $196.6 million in revenues compared to $177.8 million for the same quarter in 2022, beating analysts' average estimate.
Apr 14, 2021
Jun 15, 2020
Yourgene Health Gets CE Mark for Iona NIPT Test
Nov 8, 2019
Sep 13, 2019
May 29, 2018
Myriad Genetics to Acquire Counsyl for $375M
Nov 6, 2017
Counsyl Raises $80M
Oct 16, 2017
Jul 14, 2017